Baseline cohort | Year one cohort | |||
Stage II | Stage III and IV | Stage II | Stage III and IV | |
N | 74 | 74 | 94 | 82 |
Age | 65 | 64 | 63 | 64 |
Males (%) | 65 | 68 | 64 | 79 |
Pack years | 48 | 49 | 51 | 56 |
FEV1 (L) | 1.6 | 0.94 | 1.6 | 0.94 |
FEV1% Predicted | 57 | 34 | 57 | 34 |
FEV1/FVC ratio | 51 | 36 | 52 | 38 |
Exacerbation rates/year | 1.06 | 2.00 | 0.90 | 2.01 |
% White | 100 | 99 | 99 | 98 |
% Other race | 0 | 1 | 1 | 2 |
% Low LAA | 75 | 26 | 66 | 34 |
% High LAA | 27 | 73 | 30 | 70 |
% Reversibility | 11 | 8 | 12 | 13 |
% Inhaled Steroid use | 79 | 87 | 83 | 91 |
% LABA use | 74 | 92 | 83 | 89 |
% Tiotropium use | 43 | 49 | 30 | 27 |
Total cell count (x 106) | 4.10 | 3.46 | 3.40 | 3.17 |
Sputum neutrophil (%) | 79 | 87 | 80 | 82 |
Sputum macrophage (%) | 18 | 9 | 17 | 14 |
Sputum eosinophil (%) | 1 | 1 | 1 | 2 |
Sputum lymphocyte (%) | 1 | 1 | 1 | 1 |
Exacerbation rates were calculated over the three years of the study. Values are means.
LABA, long acting beta agonist.